Institutional members access full text with Ovid®

Share this article on:

Cervical Cancers After Human Papillomavirus Vaccination

Joura, Elmar A. MD; Garland, Suzanne M. MBBS, MD

doi: 10.1097/AOG.0b013e3181aa8f9f
Letters to the Editor

Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, Medical University Vienna, Vienna, Austria (Joura)

Royal Women’s Hospital and Royal Children’s Hospital Melbourne, University of Melbourne, Melbourne, Australia (Garland)

Financial Disclosure: Dr. Joura conducted a human papillomavirus trial and received funding through his institution from Merck (Whitehouse Station, NJ) and GlaxoSmithKline (Rixensart, Belgium). He has also received lecture fees from Merck, GlaxoSmithKline, and Sanofi Pasteur MSD (Lyon, France). Dr. Garland has received advisory fees and grant support from Common-wealth Serum Laboratories (Victoria, Australia) and GlaxoSmithKline and lecture fees from Merck and GlaxoSmithKline. She has also received funding from her institution to conduct vaccine studies for Merck and GlaxoSmithKline.

Editor’s Note: The authors declined to respond.

© 2009 by The American College of Obstetricians and Gynecologists.